title: Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.
abstract: This review revises the reclassification of the membranoproliferative glomerulonephritis (MPGN) after the consensus conference that by 2015 reclassified all the glomerulonephritis basing on etiology and pathogenesis, instead of the histomorphological aspects. After reclassification, two types of MPGN are to date recognized: The immunocomplexes mediated MPGN and the complement mediated MPGN. The latter type is more extensively described in the review either because several of these entities are completely new or because the improved knowledge of the complement cascade allowed for new diagnostic and therapeutic approaches. Overall the complement mediated MPGN are related to acquired or genetic cause. The presence of circulating auto antibodies is the principal acquired cause. Genetic wide association studies and family studies allowed to recognize genetic mutations of different types as causes of the complement dysregulation. The complement cascade is a complex phenomenon and activating factors and regulating factors should be distinguished. Genetic mutations causing abnormalities either in activating or in regulating factors have been described. The diagnosis of the complement mediated MPGN requires a complete study of all these different complement factors. As a consequence, new therapeutic approaches are becoming available. Indeed, in addition to a nonspecific treatment and to the immunosuppression that has the aim to block the auto antibodies production, the specific inhibition of complement activation is relatively new and may act either blocking the C5 convertase or the C3 convertase. The drugs acting on C3 convertase are still in different phases of clinical development and might represent drugs for the future. Overall the authors consider that one of the principal problems in finding new types of drugs are both the rarity of the disease and the consequent poor interest in the marketing and the lack of large international cooperative studies.
authors.affiliation: Maurizio Salvadori, Department of Renal Transplantation, Careggi University Hospital, 50139 Florence, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Salvadori
authors.affiliation: Maurizio Salvadori, Department of Renal Transplantation, Careggi University Hospital, 50139 Florence, Italy.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Rosso
keywords: C3 glomerulopathies; Complement dysregulation; Dense deposit disease; Glomerulonephritis reclassification; Membranoproliferative glomerulonephritis; Targeting complement pathways